Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard […]

SAN DIEGO — Final results of the phase 3 Andromeda study confirmed that adding daratumumab (DARA) — a human CD38-targeting monoclonal antibody — to bortezomib, cyclophosphamide, […]

The addition of atezolizumab to standard neoadjuvant chemotherapy followed by adjuvant atezolizumab did not significantly improve event-free survival (EFS) in patients with stages II-III triple-negative breast […]

SAN ANTONIO — A large trial has begun to make the case for active surveillance as an alternative to immediate surgery for low-risk ductal carcinoma in […]

SAN ANTONIO — Weekly patient-reported outcomes monitoring combined with an automated alert system improved fatigue and overall quality of life and prolonged survival in patients with […]

New biomarker analyses from the phase 3 KEYNOTE-522 trial provide insights into the biological factors that may influence response to pembrolizumab plus chemotherapy in early-stage triple-negative […]

SAN ANTONIO — Patients with early-stage, node-negative, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and a high risk for recurrence benefited […]

SAN ANTONIO — Women 70 years or older with early luminal A-like breast cancer who received postoperative radiotherapy alone following surgery reported having better health-related quality […]